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ABSTRACT
Introduction: : Human infections with helminth worm parasites are extraordinarily prevalent across 
tropical and subtropical parts of the world, and control relies primarily on drugs that offer short-term 
suppression of infection. There is an urgent need for new vaccines that would confer long-lived 
immunity, protecting children in particular and minimizing community transmission.
Areas covered: : This article discusses the development of helminth vaccines, from the first successful 
veterinary vaccines that demonstrated the feasibility of inducing protective immunity to helminths, to 
more recent initiatives to test human helminth antigens. The field has focussed primarily on evaluating 
individual antigens that could constitute targets amenable to antibody attack to inhibit parasite 
establishment. In a new direction, vaccines employing extracellular vesicles released by helminths 
have also given exciting results.
Expert opinion: : Taking into account the complex life cycles and sophisticated immune evasion 
strategies of many helminths, a combination of antigens and approaches designed to target essential 
functional pathways of the parasite will be required to achieve a high level of protection in future anti- 
helminth vaccines.
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Vaccines against human helminth parasites remain one of the 
greatest challenges in global medicine [1,2]. Helminth round-
worm (nematodes) and flatworm (cestodes and trematodes) 
infect over a billion people across many low/middle-income 
countries [3], with high prevalence in children and a myriad of 
pathological effects [4]. Drug treatments are of limited effi-
cacy, with populations rapidly reinfected and showing little 
sign of acquired immunity from natural exposure to infections 
[5,6]. Hence, there is a burning need for vaccines that would 
interrupt transmission and confer lasting benefits on many of 
the poorest communities in the world [7,8].
Efforts to generate vaccines against helminths date back 
50 years to the development of a dog hookworm vaccine 
using irradiated infective larvae of Ancylostoma caninum 
[9,10]. While not a commercial success (as the vaccine did 
not entirely prevent transmission), this demonstrated that 
vaccine-induced immunity was possible, and paved the way 
for a similar irradiated larval vaccine (Huskvac) for lungworm 
(Dictyocaulus viviparus) in cattle [11]. A separate initiative, 
also in the veterinary arena, led to the development of a 
vaccine based on purified intestinal antigens of 
Haemonchus contortus (the ‘Barber’s Pole’ worm), now mar-
keted as Barbervax [12,13]. Finally, successful recombinant 
vaccines have been pioneered against cestode tapeworms 
of livestock [14], now marketed in a number of tropical 
countries as CysVax (for Taenia solium in pigs) and Hidatil 
(for Echinococcus granulosus in ruminants).
Despite these successes, we still lack vaccines for human 
helminth infections. In part, irradiated larval strategies could 
not be applied to humans on any scale, and there are far 
greater regulatory hurdles than in the veterinary setting. 
Nevertheless, hundreds of candidate antigens have been 
tested in model systems for filariasis [15,16], schistosomiasis 
[17–19], soil-transmitted nematodes [20] and other human 
helminth parasites [21], with trials in endemic populations 
under way for hookworm and schistosomiasis [22]. But there 
remain some fundamental obstacles to achieve fully effective 
vaccines against human helminth parasites.
2. Challenges for helminth vaccines
A primary consideration is the nature of helminth infections, in 
which parasites migrate through different tissues, maturing 
from infective stages to adult worms, presenting a ‘moving 
target’ in more senses than one. Secondly, helminths are 
generally large, resilient organisms that may require a sus-
tained and multi-pronged immune assault, rather than the 
one-off ‘lethal hit’ that the immune system can deliver to a 
virus-infected cell. Thirdly, they express multiple immune eva-
sion strategies, at many levels and most likely in a redundant 
fashion, that subvert and defuse vaccine-induced immunity.
These factors militate against the conventional single sub-
unit vaccine development approach that has proved success-
ful for microbial pathogens. In contrast, for a single helminth 
antigen to induce effective protective immunity, that target 
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would have to be sufficiently expressed over time, and be 
essential for survival if a vaccine were not simply to select 
for parasites that lose expression of the antigen. It is also to be 
expected that many helminth antigens will show polymorph-
isms across natural populations; while this dimension is rarely 
evaluated, a combination approach will minimize the danger 
of vaccine failure due to antigenic variation of the key target 
epitope.
A further problem with single subunit strategies is that all 
induce partial rather than complete immunity. Even in animal 
models, with little variation in host or parasite, immunization 
with individual antigens is often considered successful if 50% 
worm load reductions are achieved, and trials in endemic 
human populations with single antigen vaccines have so far 
been disappointing [23]. Vaccines that reduce worm loads by 
50% may not compromise the ability of helminths to down-reg-
ulate the immune system, and will do little to break transmission; 
those that block egg production while leaving adult worms 
unscathed may do little to benefit the individual receiving the 
vaccine. Hence, a synergistic approach will often be needed. The 
cestode vaccines that succeed with a single target (To45 or Eg95), 
are exceptional as the target oncosphere stage is small enough 
(~20 µm) to be lysed by complement, and expresses a minimal 
number of products essential for its invasion of the intestinal 
mucosa [24]. Among other helminth organisms, the schistosome 
protein Sm-p80 (calpain) individually induces high levels of pro-
tection in baboons and is currently awaiting clinical trials [25,26], 
but no other single protein has proved so effective. Most anti- 
helminth vaccines may therefore need to be multi-component 
‘cocktails,’ as successfully applied to a sheep nematode [27] and 
more recently explored with the human filarial parasite Brugia 
malayi [28]. Although posing considerable obstacles, for example, 
if each individual component must be produced and validated 
under GMP conditions, new technologies such as mRNA vaccines 
[29] offer more rapid development and could facilitate the combi-
nation of multiple antigens into a single immunogen.
A widely discussed challenge for helminth vaccines is the 
immunization of individuals who have been previously 
exposed, and/or are currently infected with parasites that 
profoundly manipulate the host immune system [30]. 
Preexisting IgE responses in adult recipients of the N. amer-
icanus ASP-2 antigen led its discontinuation in the first itera-
tion of the human hookworm vaccine [31], although it may 
still be suitable for vaccination of infants prior to their first 
exposure. Developing successful vaccines against helminths 
also requires appreciation of the immunomodulatory effects 
that may persist in dampening immunity, particularly as infec-
tions are known to inhibit responses to microbial vaccines 
[32,33]. Thus, prior infection could confound vaccination either 
by hyper-reactivity to vaccine antigens, or conversely by 
‘immunoregulatory memory’ that would represent a form of 
antigen-specific immune tolerance that could prevent 
responses to a helminth vaccine.
3. Mechanism-led approaches
Historically, helminth antigen identification strategies have 
been empiricalfor example, screening for antigens recog-
nized by serum antibodies from exposed but uninfected 
(‘putatively immune’) individuals, with less consideration 
given to biological context (e.g. expression through the 
life cycle, essential function and accessibility to the 
immune system. With the explosion in helminth genomics, 
transcriptomics and proteomics, candidate antigens are 
plentiful and require thoughtful criteria to select the 
most effective.
This brings to the fore the question of mechanism; a clear 
understanding of how the immune system targets and elim-
inates helminth parasites is required for a rational choice of 
vaccine antigens. Again, adopting paradigms of antibody- 
mediated cytotoxicity or lytic T cells from the microbial 
world can be misleading – rather than sudden death, hel-
minths are degraded more slowly and by the mass effect of 
innate immune cells, either by swarming and surrounding in 
the tissues, or bathing in mucus and inhibitory products in the 
lumen of the gut. Over time, these progressively compromise 
parasite fitness, first reducing egg production (the ‘anti- 
fecundity’ effect) and eventually causing the death of the 
whole organism [34]. Choosing antigens that represent key 
vulnerabilities of the parasite, as considered below, is of cen-
tral importance; so too is the recognition of responder T cell 
modes (primarily but not always Th2). However, few discus-
sions of helminth vaccines have as yet included pathways to 
promote mobilization of the innate effector populations 
(macrophages, eosinophils, and even neutrophils) that would 
be required to block worm establishment [35].
Across the helminth field, two lines of approach have been 
able to integrate mechanism with rational antigen selection. A 
long-standing example is that of targetting intestinal enzymes 
of hematophagous parasites such as H. contortus in sheep, and 
N. americanus in humans, or of flatworms established in the 
vasculature or tissues [36,37]. Here, the logic is that internal 
parasite constituents exposed on their intestinal membrane 
represent ‘hidden antigens’ which have not been subject to 
immune pressure, and for which even infected individuals 
have no preexisting antibody. Hence, vaccination will generate 
antibodies that, when ingested with blood by the parasites, 
will interfere with worm nutrition and eventually cause their 
demise. This principle underlies the Barbervax vaccine, using 
industrial-scale extraction from native parasites, and the sec-
ond generation human hookworm vaccine currently under 
evaluation [38]. The latter is a bi-valent entity with recombi-
nant APR-1 (aspartyl protease which digests hemoglobin) and 
GST-1 (gluathione S-transferase which detoxifies heme). In 
Article highlights
● Helminth vaccines have been shown to be effective in the veterinary 
arena
● Subunit vaccines with single antigens are less likely to succeed for 
human helminth parasites
● Vaccine design should be informed by mechanistic understanding of 
immunity
● Combinatorial antigens are likely to be required for effective vaccina-
tion, and would offer advantages of vaccines targeting multiple 
stages and species
● Extracellular vesicles may represent conserved targets suitable for 
vaccine development.
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combination, antibodies are thought to prevent parasites from 
digesting blood normally. While this is an attractive strategy, 
with proven efficacy in the case of H. contortus, it is limited to 
those species that feed on blood, and targets the mature 
stages of those species, rather than immature, tissue-migra-
tory larvae. In addition, if the target antigens are never pre-
sented to the immune system, there will be no natural 
boosting by subsequent parasite infection or exposure, neces-
sitating re-vaccination to maintain antibody levels.
Further examples of this physiology-led approach are 
found in the current generation of Schistosome vaccines, 
including Sm-p80, which is highly expressed on the adult 
worm tegument being implicated in surface turnover and 
immune evasion, and as mentioned above generated a high 
level of protection in baboons [25,26]. Other candidates being 
actively pursued are tetraspanin (TSP)-2, again linked to the 
tegumental membrane, FABP/Sm-14, a widely expressed fatty 
acid binding and uptake protein, as well as the glutathione S- 
transferase Sh28GST, which in Schistosomes is also involved 
with muscle function [30]. Interestingly, there are suggestions 
that the existing S. mansoni vaccine antigens should be 
employed in combination [22].
A second mechanistic approach with a strong immuno-
logical foundation has been to target the suite of factors 
that helminths release to modify their environment and 
down-modulate the host immune system. Indeed, many of 
the first experimental vaccines in different helminth models 
utilized released molecules (termed excretory/secretory or 
ES products) and achieved high levels of protection [39]. 
However, these are generally complex mixtures and in very 
few cases have individual ES proteins been shown to induce 
protective immunity. Most probably, the redundancy of 
parasite products is responsible for lack of efficacy, return-
ing the discussion to the need for multicomponent vac-
cines. In a study on a murine model system, 
Heligmosomoides polygyrus, immunization with ES products 
elicited sterile immunity to challenge infection; from the 
mixture, a combination of 3 proteins (VAL-1/2/3) were suffi-
cient to drive immunity [40]. Interestingly these are mem-
bers of the same gene family as N. americanus ASP-2, which 
was an earlier human vaccine candidate, and a number of 
homologs tested as vaccines for veterinary nematodes [41]. 
It remains to be determined if there is functional homology 
between members of this gene family in the different host- 
parasite combinations, but their prominence as effective 
immunogens does indicate a key role in parasite modula-
tion of the host [41].
4. Extracellular vesicles – a new target
Most recently, a new dimension in helminth vaccines has 
emerged with the discovery that many parasites release within 
their ES material not only soluble macromolecules, but lipid- 
bound vesicles containing a cargo of proteins and small RNAs 
[42–44]. Importantly, these extracellular vesicles (EVs) exert 
significant immunomodulatory effectsfor example, inhibiting 
the expression of the receptor for IL-33 that is required to 
initiate the type 2 immune response [43], and down- 
regulating the activation of macrophages involved in innate 
immunity to helminths [45].
In the model H. polygyrus system, secreted EVs were found 
to evoke a strong serum antibody response, and a high degree 
(>80%) of protective immunity when administered with alum 
adjuvant [45]. In vitro, anti-EV antibodies promoted uptake of 
vesicles by macrophages into the lysosomal pathway, dis-
abling them from exerting modulatory effects. Thus, in the 
presence of antibodies macrophages were protected from 
immunosuppression and retained their type 2 profile. 
Subsequently, further studies reported that immunization 
with EVs from the trematode Opisthorchis viverrini, and the 
nematode Trichuris muris, induce a protective immune 
response [46,47].
Analysis of the proteins associated with H. polygyrus EVs 
revealed a prominent set of components associated with the 
apical intestinal epithelium of nematodes [43], including 
homologs of antigens represented in Barbervax, the prepara-
tion of H. contortus gut material, such as H11, as well tetra-
spanins discussed above which are already candidate vaccines 
for S. mansoni. Immunogenic tetraspanins also were abundant 
in a proteomic analysis of S. haematobium EVs, alongside other 
vaccine candidates such as GST [48], giving credence to the 
possibility that immunization with these antigens targets EVs 
as well as parasite tissues.
Furthermore, vaccination with individual EV antigens, 
rather than intact EVs, may suffice to generate an antibody 
response that will neutralize the total immunomodulatory 
cargo – including small RNAs [44]. In this setting, parasites 
release combinations of immune modulators that are pack-
aged into the EVs, to target host cells such as the macrophage 
and block protective immunity. Due to the discrete nature of 
the vesicle, antibody binding to any of its surface epitopes 
should result in uptake of EVs by phagocytes, and thereby 
destruction of the whole entity. Hence, targetting EVs by 
vaccinating against a single surface antigen could achieve 
exactly the combinatorial effect that is required for immunity. 
In practice, an anti-EV vaccine would be most potent target-
ting multiple-surface constituents, especially if the vesicles are 
heterogeneous with respect to membrane protein expression, 
or (as it likely) differ in composition between immature and 
mature parasite stages.
5. Expert opinion
Historically, the field of human helminth vaccine development 
has been dominated by the search for individual antigens that 
would generate protective immunity against a single species 
of parasite. However, helminths are complex organisms with 
sophisticated immune evasion mechanisms, and immunity is 
likely to require a co-ordinated attack on many fronts. Hence, 
we may already have in hand key antigenic targets but need 
to consider how to employ them to best effect, in combina-
tions and with optimal adjuvants that induce the most effec-
tive mode of immune response. Hence, it may be that the era 
of discovering new candidate antigens for the major human 
helminths will soon draw to a close, replaced by a strategy of 
selecting, combining, and configuring the known candidates, 
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potentially through modifications to maximize immunogeni-
city and minimize any safety concerns.
Whether based on conventional protein antigens, or EV- 
based components, vaccines can be developed that target 
both larvae and adults, preempting both pathology and 
transmission; immunity to helminths can act to degrade 
their fitness, as observed in ‘anti-fecundity immunity’ in 
which surviving adult worms produce fewer eggs. 
Accordingly, it may be expected that even if parasites 
survive immune attack as larvae, they will be less able to 
resist expulsion once they mature to adults. In this setting, 
multi-stage vaccines should show a synergistic effect, and 
would be particularly desirable where tissue-migrating lar-
vae are as pathogenic as intestinal adults of the same 
species.
In the case of functional ‘hidden antigens’ and those from 
EVs, there is more likelihood of conserved epitopes shared 
across species so that a pan-helminth vaccine might be pos-
sible, and there is a further possibility of a compound vaccine 
presenting homologous antigens from multiple species to 
create the pan-helminth vaccine discussed previously [49]. 
Strategically, a vaccine that targetted multiple helminth spe-
cies would be not only of logistical value in delivering protec-
tion to low-income communities, but would also avoid the 
possibility that clearance of one helminth species could pro-
vide greater opportunities for others.
Combinatorial vaccines, however, imply a substantial 
growth in permutations that will require testing, shining a 
greater spotlight on screening and trial capacity. The pro-
blem is accentuated because animal models are distant 
from the human setting for most helminths, although 
Schistosoma mansoni infects rodents and the human and 
mouse Trichuris species are closely related. On a positive 
note, veterinary helminth vaccines are being actively pur-
sued [50] and can act as excellent pathfinders across a 
range of issues, from antigen validation, selection of combi-
nations, and optimal mode of immune response induction, 
each against a backdrop of a pan-helminth vaccine agenda. 
Moreover, exciting progress has been made on controlled 
human infection with hookworm [51,52,53] and schisto-
somes [54] that will more quickly and rigorously evaluate 
front-running vaccine formulations.
Undoubtedly, the pipeline to realizing a final vaccine for 
human use is long and difficult, with multiple hurdles to 
progress each candidate through the ‘critical path’ to approval 
[2]. Possibly, a half-way house can be established in which 
first-generation vaccines that do not yet reach full efficacy can 
be combined with existing drug administration regimens to 
dramatically lower the burden of human helminth infections. 
Clearly, this issue is becoming ever more urgent to address, 
and only sufficient mobilization of resources may stand 
between us and final realization of new vaccines against 
these parasitic scourges.
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